News

Recent news about Panacea Venture and select portfolio companies

September 16, 2025

Mytrelle Announces Nature Medicine Publication of Interim Results

Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease

September 16, 2025

Mytrelle Announces Nature Medicine Publication of Interim Results

Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease

September 3, 2025

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd

Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia. XWPharma to receive $20 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales

September 3, 2025

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd

Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia. XWPharma to receive $20 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales

July 16, 2025

Evox Therapeutics Expands Scientific Advisory Board

Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases

July 16, 2025

Evox Therapeutics Expands Scientific Advisory Board

Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases

July 16, 2025

TPEx-Listed HanchorBio Advances Global Impact of HCB101 Immunotherapy

TAIPEI, SHANGHAI and SAN FRANCISCO, July 16, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827.TWO), a pioneer of immunotherapy biologics, is announcing its official listing on the Taipei Exchange (TPEx) Emerging Stock Board under the ticker symbol 7827.TWO and the name Hanchor-KY

July 16, 2025

TPEx-Listed HanchorBio Advances Global Impact of HCB101 Immunotherapy

TAIPEI, SHANGHAI and SAN FRANCISCO, July 16, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827.TWO), a pioneer of immunotherapy biologics, is announcing its official listing on the Taipei Exchange (TPEx) Emerging Stock Board under the ticker symbol 7827.TWO and the name Hanchor-KY

July 8, 2025

Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy

Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.

July 8, 2025

Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy

Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.